Considerations for Potential Future Therapeutic Use of Psychedelic Drugs Public Hearing

The U.S. Food and Drug Administration (FDA), in collaboration with federal partners, hosted a public hearing on the regulatory and clinical considerations for the potential future therapeutic use of psychedelic drug products in supervised and supportive settings. Stakeholders and researchers addressed safety protocols, study design challenges, and the framework required for evaluating psychedelic-assisted therapies.